Clinical Trial Update: A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated the mode of administration and safety of EUR-1008 (APT-1008) in infants aged 1 to 12 months with cystic fibrosis and exocrine pancr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• EUR-1008 (APT-1008)

Snippet

Sponsor: Forest Laboratories | Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency | Phase 4 | Status: COMPLETED | Results posted: 2014-04-10